[go: up one dir, main page]

CN111712521A - Cd38蛋白抗体及其应用 - Google Patents

Cd38蛋白抗体及其应用 Download PDF

Info

Publication number
CN111712521A
CN111712521A CN201980012880.5A CN201980012880A CN111712521A CN 111712521 A CN111712521 A CN 111712521A CN 201980012880 A CN201980012880 A CN 201980012880A CN 111712521 A CN111712521 A CN 111712521A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012880.5A
Other languages
English (en)
Other versions
CN111712521B (zh
Inventor
吕明
丁晓然
缪仕伟
谈彬
王学恭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Original Assignee
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sumgen Biotech Co Ltd, Sumgen MAb Beijing Biotech Co Ltd filed Critical Hangzhou Sumgen Biotech Co Ltd
Priority to CN202210259987.3A priority Critical patent/CN114835809A/zh
Publication of CN111712521A publication Critical patent/CN111712521A/zh
Application granted granted Critical
Publication of CN111712521B publication Critical patent/CN111712521B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明提供了一种抗体或其抗原结合片段，其以1×10‑9M以下的KD值与CD38蛋白相结合。所述抗体或其抗原结合片段对于CD38蛋白的特异性识别结合能力强，可通过抗体依赖的细胞介导的细胞毒性ADCC、补体依赖的细胞毒性CDC和/或细胞凋亡杀死CD38+细胞。本发明还提供了所述抗体或其抗原结合片段在预防和治疗肿瘤中的应用。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201980012880.5A 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用 Active CN111712521B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210259987.3A CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101448174 2018-02-12
CN201810144817.4A CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
PCT/CN2019/074806 WO2019154421A1 (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210259987.3A Division CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Publications (2)

Publication Number Publication Date
CN111712521A true CN111712521A (zh) 2020-09-25
CN111712521B CN111712521B (zh) 2022-03-15

Family

ID=67547850

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810144817.4A Active CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN202210259987.3A Pending CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用
CN201980012880.5A Active CN111712521B (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201810144817.4A Active CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN202210259987.3A Pending CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Country Status (11)

Country Link
US (1) US11713357B2 (zh)
EP (1) EP3753955A4 (zh)
JP (1) JP7333523B2 (zh)
KR (1) KR102770962B1 (zh)
CN (3) CN110144008B (zh)
AU (1) AU2019218518B2 (zh)
BR (1) BR112020016271A2 (zh)
CA (1) CA3091492C (zh)
SG (1) SG11202007443XA (zh)
TW (1) TWI818952B (zh)
WO (1) WO2019154421A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
WO2023098813A1 (en) * 2021-12-03 2023-06-08 Nanjing Leads Biolabs Co., Ltd. Antibodies binding cd38 and uses thereof
WO2024183634A1 (en) * 2023-03-09 2024-09-12 Norroy Bioscience Co., Ltd. Radiolabeled antibody conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
CN101616933A (zh) * 2006-10-19 2009-12-30 赛诺菲-安万特 用于治疗癌症的新型抗-cd38抗体
CN103282383A (zh) * 2010-12-30 2013-09-04 武田药品工业株式会社 抗cd38抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
RU2402568C2 (ru) 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
KR20150139636A (ko) * 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
EP2342220B1 (en) * 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
CN108136218B (zh) * 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
HUE053366T2 (hu) * 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
AU2018280871B2 (en) * 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
CA3066547A1 (en) 2017-06-08 2018-12-13 Black Belt Therapeutics Limited Cd38 modulating antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
CN101616933A (zh) * 2006-10-19 2009-12-30 赛诺菲-安万特 用于治疗癌症的新型抗-cd38抗体
CN103282383A (zh) * 2010-12-30 2013-09-04 武田药品工业株式会社 抗cd38抗体

Also Published As

Publication number Publication date
SG11202007443XA (en) 2020-09-29
US20210024645A1 (en) 2021-01-28
CN110144008A (zh) 2019-08-20
CN111712521B (zh) 2022-03-15
AU2019218518B2 (en) 2025-07-10
CA3091492A1 (en) 2019-08-15
TW201934577A (zh) 2019-09-01
CN110144008B (zh) 2021-03-19
AU2019218518A1 (en) 2020-10-01
WO2019154421A1 (zh) 2019-08-15
RU2020129820A3 (zh) 2022-03-14
KR20200120937A (ko) 2020-10-22
KR102770962B1 (ko) 2025-02-24
TWI818952B (zh) 2023-10-21
EP3753955A1 (en) 2020-12-23
BR112020016271A2 (pt) 2020-12-15
US11713357B2 (en) 2023-08-01
JP7333523B2 (ja) 2023-08-25
RU2020129820A (ru) 2022-03-14
EP3753955A4 (en) 2021-12-08
CA3091492C (en) 2023-10-10
CN114835809A (zh) 2022-08-02
JP2021512652A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
CN111712521A (zh) Cd38蛋白抗体及其应用
CA2987118C (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
CN112135626A (zh) 抗tigit抗体及其用途
JP2021506244A5 (zh)
CN115003333A (zh) Pvrig结合蛋白及其医药用途
JP2017535257A5 (zh)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2021512652A5 (zh)
JP2023093753A5 (zh)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JPWO2019224711A5 (zh)
JP2017521054A5 (zh)
JP2024024114A5 (zh)
RU2018106456A (ru) Антитело к epha4
CN110662764B (zh) 抗程序性死亡配体1(pd-l1)抗体及其治疗用途
RU2017123022A (ru) Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии
JPWO2021224913A5 (zh)
CN112805297B (zh) 抗人类pd-l1抗体及其用途
JPWO2020227457A5 (zh)
JPWO2020123664A5 (zh)
JPWO2022051591A5 (zh)
JPWO2020144178A5 (zh)
JPWO2021119531A5 (zh)
JPWO2021259335A5 (zh)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029523

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant